Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Licenses Array Tech to Epigenomics for Oncology Tests

NEW YORK, June 27 (GenomeWeb News) - Affymetrix granted Epigenomics non-exclusive access to its microarray technology to develop microarray-based in vitro diagnostic tests for oncology, Epigenomics said today.


Epigenomics said the agreement complements its strategic alliance with Qiagen for sample preparation, announced last year.


Epigenomics will use the technologies to develop a platform for pathology tests based on its proprietary DNA methylation methods. Epigenomics will first develop pathology tests in prostate and breast cancer, the company said.


The company plans to transfer its molecular classification test for prostate cancer onto the Affymetrix platform to use it in clinical trials for FDA approval of the assay, scheduled to start next year.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.